Ascent Group LLC Makes New $202,000 Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Ascent Group LLC has acquired a new position in Alnylam Pharmaceuticals, purchasing 749 shares valued at approximately $202,000 in the first quarter of 2023.
• Major institutional investors, including Vanguard Group and T. Rowe Price, have increased their holdings in Alnylam Pharmaceuticals, which is now owned 92.97% by such investors.
• Alnylam Pharmaceuticals recently upgraded their quarterly earnings, reporting an EPS of $0.32, significantly surpassing analysts’ estimates, alongside a revenue increase of 17.3% year-over-year.

Ascent Group LLC bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 749 shares of the biopharmaceutical company's stock, valued at approximately $202,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Parkman Healthcare Partners LLC lifted its stake in Alnylam Pharmaceuticals by 78.3% during the first quarter. Parkman Healthcare Partners LLC now owns 68,938 shares of the biopharmaceutical company's stock valued at $18,615,000 after purchasing an additional 30,266 shares during the last quarter. Nissay Asset Management Corp Japan ADV lifted its stake in Alnylam Pharmaceuticals by 1.7% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 16,214 shares of the biopharmaceutical company's stock valued at $4,378,000 after purchasing an additional 267 shares during the last quarter. Integrated Wealth Concepts LLC lifted its stake in Alnylam Pharmaceuticals by 9.0% during the first quarter. Integrated Wealth Concepts LLC now owns 2,739 shares of the biopharmaceutical company's stock valued at $740,000 after purchasing an additional 227 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Alnylam Pharmaceuticals during the first quarter valued at approximately $41,305,000. Finally, Edmond DE Rothschild Holding S.A. lifted its stake in Alnylam Pharmaceuticals by 18.2% during the first quarter. Edmond DE Rothschild Holding S.A. now owns 318 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 49 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 6,979 shares of the firm's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $453.27, for a total value of $3,163,371.33. Following the transaction, the chief executive officer directly owned 56,221 shares in the company, valued at approximately $25,483,292.67. This trade represents a 11.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Dennis A. Ausiello sold 31,448 shares of the firm's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the completion of the transaction, the director owned 911 shares in the company, valued at $397,724.38. The trade was a 97.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 75,594 shares of company stock worth $33,968,256 in the last ninety days. 1.20% of the stock is owned by insiders.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY traded down $4.75 during midday trading on Monday, reaching $461.14. The stock had a trading volume of 910,054 shares, compared to its average volume of 1,109,281. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $484.21. The firm's fifty day simple moving average is $404.20 and its 200-day simple moving average is $319.41. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The stock has a market capitalization of $60.45 billion, a P/E ratio of -186.70 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. During the same period last year, the business posted ($0.13) EPS. Alnylam Pharmaceuticals's revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on ALNY. Canaccord Genuity Group increased their target price on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a "buy" rating in a research note on Friday, August 1st. UBS Group upped their price objective on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a "buy" rating in a research note on Friday, August 1st. BMO Capital Markets upped their price objective on shares of Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an "outperform" rating in a research note on Friday, September 5th. Citigroup upped their price objective on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a "buy" rating in a research note on Tuesday, September 2nd. Finally, Wall Street Zen lowered shares of Alnylam Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 5th. Twenty-three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $421.28.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.